Literature DB >> 15214881

High-level fluoroquinolone resistance in a clinical Streptoccoccus pyogenes isolate in Germany.

R R Reinert1, R Lütticken, A Al-Lahham.   

Abstract

An isolate of Streptococcus pyogenes isolated from a 63-year-old woman with a serious wound infection was found to be highly resistant to fluoroquinolones (levofloxacin MIC > or = 32 mg/L). DNA amplification and sequencing revealed a serine-81 to phenylalanine substitution in gyrA and three substitutions in parC: serine-79 to phenylalanine, aspartic acid-91 to asparagine, and serine-140 to proline. To our knowledge, this is the first report from a European country of a clinical isolate of S. pyogenes with high-level fluoroquinolone resistance.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15214881     DOI： 10.1111/j.1469-0691.2004.00890.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


  14 in total

1.  Streptococcus pyogenes pharyngeal isolates with reduced susceptibility to ciprofloxacin in Spain: mechanisms of resistance and clonal diversity.

Authors:  Sebastián Albertí; Guadalupe Cortés; Cesar García-Rey; Carmen Rubio; Fernando Baquero; José Angel García-Rodríguez; Emilio Bouza; Lorenzo Aguilar
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal.

Authors:  Renato Pires; Carmen Ardanuy; Dora Rolo; Ana Morais; António Brito-Avô; José Gonçalo-Marques; Josefina Liñares; Ilda Santos-Sanches
Journal:  Antimicrob Agents Chemother       Date:  2010-03-29       Impact factor: 5.191

3.  Evaluation of the Potency, Neutralizing Antibody Response, and Stability of a Recombinant Fusion Protein Vaccine for Streptococcus pyogenes.

Authors:  E Burlet; H HogenEsch; A Dunham; G Morefield
Journal:  AAPS J       Date:  2017-03-10       Impact factor: 4.009

Review 4.  Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.

Authors:  A Dalhoff
Journal:  Infection       Date:  2012-03-30       Impact factor: 3.553

5.  Prevalence and characterization of invasive isolates of Streptococcus pyogenes with reduced susceptibility to fluoroquinolones.

Authors:  Jeff Powis; Allison McGeer; Carla Duncan; Ryan Goren; Joyce C S de Azavedo; Darrin J Bast; Sylvia Pong-Porter; Tony Mazzulli; Karen Green; Barbara Willey; Donald E Low
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

6.  Fluoroquinolone resistance in invasive Streptococcus pyogenes isolates due to spontaneous mutation and horizontal gene transfer.

Authors:  M W R Pletz; L McGee; C A Van Beneden; S Petit; M Bardsley; M Barlow; K P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

7.  Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.

Authors:  Milagrosa Montes; Esther Tamayo; Beatriz Orden; Julián Larruskain; Emilio Perez-Trallero
Journal:  Antimicrob Agents Chemother       Date:  2009-10-05       Impact factor: 5.191

8.  An intrinsic pattern of reduced susceptibility to fluoroquinolones in pediatric isolates of Streptococcus pyogenes.

Authors:  S Steve Yan; Paul C Schreckenberger; Xiaotian Zheng; Nancy A Nelson; Susan M Harrington; Joyce Tjhio; Daniel P Fedorko
Journal:  Diagn Microbiol Infect Dis       Date:  2008-06-12       Impact factor: 2.803

9.  Update on the clinical utility and optimal use of cefditoren.

Authors:  José Barberán; Lorenzo Aguilar; María-José Giménez
Journal:  Int J Gen Med       Date:  2012-05-21

10.  Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Authors:  Axel Dalhoff
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.